SCHEMBL2523974

SCHEMBL2523974

N#Cc1cccc(C2=CC[C@@H](C(=O)O)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.47
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
XDH P47989 1/20 0.43
SLC22A12 Q96S37 1/20 0.43
MCHR1 Q99705 2/20 0.41
FFAR2 O15552 1/20 0.41
PAX8 Q06710 1/20 0.40
F11 P03951 1/20 0.38
PIN1 Q13526 1/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
USP30 Q70CQ3 3/20 0.38
CLK4 Q9HAZ1 1/20 0.37
UCHL1 P09936 1/20 0.37
GSK3B P49841 1/20 0.37
SCD O00767 1/20 0.37
SCD5 Q86SK9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523971 1.00 NOTUM (0.47) NOTUMPDE4APDE4BPDE4CPDE4D
SCHEMBL2521851 0.85 MCHR1 (0.41) NOTUMPDE4APDE4BPDE4CPDE4D
SCHEMBL2521850 0.85 MCHR1 (0.41) NOTUMPDE4APDE4BPDE4CPDE4D
SCHEMBL2511133 0.82 CNR2 (0.44) MCHR1CCNT1CDK9
SCHEMBL2511131 0.82 CNR2 (0.44) MCHR1CCNT1CDK9
SCHEMBL19746393 0.81 NPC1 (0.46) NOTUMCCNT1CDK9
SCHEMBL27617541 0.81 CLK4 (0.41) NOTUMXDHSLC22A12MCHR1CLK4
SCHEMBL12282855 0.80 CCNT1 (0.40) CCNT1CDK9
SCHEMBL28244108 0.77 DGAT1 (0.41)
SCHEMBL2520161 0.73 NOTUM (0.51) NOTUMPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558467-B1 ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2017-05-17 EP disclosed
US-8461151-B2 Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
EP-2558467-A1 ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2013-02-20 EP disclosed
WO-2011128265-A1 ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed
US-20110251183-A1 ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251183-A1 ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES OXTR, AVPR1B, AVPR1A NOTUM 3913/4885PDE4A 2902/4885PDE4B 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.